Trial Profile
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Atezolizumab
- Indications Advanced breast cancer; Early breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KATE2
- Sponsors Roche
- 01 Oct 2020 Results published in the Lancet Oncology
- 09 Mar 2020 Status changed from active, no longer recruiting to completed.
- 15 Oct 2019 Planned End Date changed from 24 Nov 2020 to 28 Jan 2020.